ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Outcome of Heart Transplantation After Pseudomonas Left Ventricular Assist Device Infection

L. Thirunavukarasu Murugan1, C. Koval2, J. Banzon3

1Infectious Disease, Cleveland Clinic, Cleveland, OH, 2Cleveland Clinic Foundation, Cleveland, OH, 3Cleveland Clinic, Cleveland, OH

Meeting: 2022 American Transplant Congress

Abstract number: 1141

Keywords: Bacterial infection, Heart transplant patients, Infection, Ventricular assist devices

Topic: Clinical Science » Heart » 63 - Heart and VADs: All Topics

Session Information

Session Name: Heart and VADs: All Topics

Session Type: Poster Abstract

Date: Sunday, June 5, 2022

Session Time: 7:00pm-8:00pm

 Presentation Time: 7:00pm-8:00pm

Location: Hynes Halls C & D

*Purpose: Pseudomonas aeruginosa (PA) is the most common gram-negative bacteria to cause left ventricular assist device (LVAD) infection. Management is difficult given limited oral antibiotic options and the presence of retained hardware. In this study, we examined the outcomes of patients who developed Pseudomonas aeruginosa LVAD infection (PA-LVADI) who subsequently received heart transplantation.

*Methods: We identified patients in our institution, older than 18 years who received an LVAD from 2011 to 2021 and followed by heart transplantation.

*Results: There were 14 patients who developed PA-LVADI then received a heart transplant. The median number of days from LVAD placement to the first isolation of PA was 451 (range 112 – 1431). All had superficial/deep driveline infection at the time of diagnosis. 3 of 14 (21%) developed PA bacteremia. 7 of 14 (50%) required surgical intervention for PA-LVADI, 6 (86%) for debridement of deep driveline infection, and 1 (14%) for mediastinitis. 10 (71.5%) received intravenous (median 50.5 days, range 5 to 277), 3 received oral and 1 received no anti-pseudomonal antibiotics prior to heart transplant. The median number of days from diagnosis of PA-LVADI to transplant was 432 (range 115 – 812). At the time of transplant, 10 of 14 (71%) still had evidence of LVADI: 8 (80%) had culture-positive PA infection, 4 with pump pocket infection, and 4 with driveline infection. 2 (20%) had infection other than PA. After the transplant, 11 (79%) received anti-pseudomonal antibiotics for at least 3 days (median 28 days, range 6 – 42). Of the 14, 1 had MDR PA as first isolate, 1 developed ciprofloxacin resistance. 13 of 14 were followed for at least 1 year after transplant. There were no post-transplant infections due to PA. All 14 patients survived. There were no episodes of rejection requiring treatment.

Characteristics at the time of LVAD placement (n=14)

Age in years, median (range)

58 (40 – 65)
Male sex, n (%) 11 (79)
LVAD type, n (%) : HeartWare ; HeartMate 2 ; HeartMate 3 3(21) ; 6(43) ; 5(36)
Heart failure etiology, n (%) : Ischemic heart disease ; Non-ischemic heart disease 6(43) ; 8(57)
Diabetes Mellitus, n (%) 4 (29)
Hypertension, n (%) 9 (64)
Chronic kidney disease, n (%) 5 (36)
Cardiac Implantable Electronic Device, n (%) 11 (79)

*Conclusions: Management of PA-LVADI can be challenging and often necessitates surgical management and prolonged IV antibiotic use. However, our patients had excellent outcomes after transplantation without recurrence of infection, suggesting that transplant is curative for PA-LVADI. Further studies are needed to compare outcomes with those who had LVADI due to other organisms.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Murugan LThirunavukarasu, Koval C, Banzon J. Outcome of Heart Transplantation After Pseudomonas Left Ventricular Assist Device Infection [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/outcome-of-heart-transplantation-after-pseudomonas-left-ventricular-assist-device-infection/. Accessed May 30, 2025.

« Back to 2022 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences